BR112013008034A2 - método para normalizar hemeostase comprometida - Google Patents

método para normalizar hemeostase comprometida

Info

Publication number
BR112013008034A2
BR112013008034A2 BR112013008034A BR112013008034A BR112013008034A2 BR 112013008034 A2 BR112013008034 A2 BR 112013008034A2 BR 112013008034 A BR112013008034 A BR 112013008034A BR 112013008034 A BR112013008034 A BR 112013008034A BR 112013008034 A2 BR112013008034 A2 BR 112013008034A2
Authority
BR
Brazil
Prior art keywords
hemeostasis
compromised
normalize
coagulation factor
fii
Prior art date
Application number
BR112013008034A
Other languages
English (en)
Portuguese (pt)
Inventor
Ann Lövgren
Kenny Hansson
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44677879&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013008034(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of BR112013008034A2 publication Critical patent/BR112013008034A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/363—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BR112013008034A 2010-10-06 2011-09-19 método para normalizar hemeostase comprometida BR112013008034A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39022410P 2010-10-06 2010-10-06
PCT/EP2011/066241 WO2012045569A1 (en) 2010-10-06 2011-09-19 Factor ii and fibrinogen for treatment of haemostatic disorders

Publications (1)

Publication Number Publication Date
BR112013008034A2 true BR112013008034A2 (pt) 2016-06-14

Family

ID=44677879

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013008034A BR112013008034A2 (pt) 2010-10-06 2011-09-19 método para normalizar hemeostase comprometida

Country Status (16)

Country Link
US (1) US9433664B2 (enExample)
EP (1) EP2624859B1 (enExample)
JP (1) JP6000259B2 (enExample)
KR (1) KR20130136988A (enExample)
CN (1) CN103221061A (enExample)
AU (1) AU2011313505B2 (enExample)
BR (1) BR112013008034A2 (enExample)
CA (1) CA2812888A1 (enExample)
DK (1) DK2624859T3 (enExample)
ES (1) ES2625153T3 (enExample)
HU (1) HUE033204T2 (enExample)
MX (1) MX343784B (enExample)
PL (1) PL2624859T3 (enExample)
RU (1) RU2606155C2 (enExample)
SG (2) SG10201508159SA (enExample)
WO (1) WO2012045569A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12171463B2 (en) 2008-10-03 2024-12-24 Femasys Inc. Contrast agent generation and injection system for sonographic imaging
PL2624859T3 (pl) 2010-10-06 2017-09-29 Medimmune Limited Czynnik ii samodzielnie lub w skojarzeniu z dalszymi czynnikami do leczenia zaburzeń hemostazy powiązanych z koagulopatią z rozcieńczenia
IL230150A0 (en) 2013-12-24 2014-09-30 Omrix Biopharmaceuticals Ltd One-component fibrin glue containing zymogens
US11744880B2 (en) 2017-02-09 2023-09-05 Csl Behring Gmbh Blood coagulation factor replacement product for use in the treatment or prophylaxis of bleedings
CN116059431A (zh) * 2021-10-29 2023-05-05 丁琴琴 一种含凝血因子的双层止血敷料及其制备方法
WO2023220412A1 (en) * 2022-05-13 2023-11-16 Cedars-Sinai Medical Center Hemostatic monitor

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0044343B1 (en) * 1980-01-28 1984-08-22 Baxter Travenol Laboratories, Inc. Prothrombin-containing therapeutic compositions and methods of producing enzymatically active blood clotting factors from prothrombin-containing blood fractions
US4501731A (en) 1983-06-27 1985-02-26 Tishkoff Garson H Treatment of disparate bleeding disorders with factor X zymogen
DE4430204A1 (de) * 1994-08-26 1996-02-29 Behringwerke Ag Arzneimittel, welches als Gegenmittel für Blut-Antikoagulanzien geeignet ist und seine Verwendung
EP0796623B1 (de) * 1996-03-20 2005-05-25 Baxter Aktiengesellschaft Pharmazeutisches Präparat zur Behandlung von Blutgerinnungsstörungen
AT409334B (de) 1997-09-19 2002-07-25 Immuno Ag Pharmazeutisches präparat enthaltend vitamin k-abhängige einzelfaktoren
US7094428B2 (en) 2000-06-16 2006-08-22 The University Of Medicine And Dentistry Of New Jersey Hemostatic compositions, devices and methods
US6825323B2 (en) 2001-01-10 2004-11-30 The United States Of America As Represented By The Secretary Of The Army Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same
DE60225118T2 (de) 2001-02-05 2009-03-05 Novo Nordisk Health Care Ag Kombinierte verwendung von faktor vii polypeptiden und faktor viii polypeptiden
US20060025336A1 (en) 2001-07-16 2006-02-02 Novo Nordisk A/S Pharmaceutical compositions comprising combinations of factor VII polypeptides and aprotinin polypeptides
JP2004534855A (ja) 2001-07-20 2004-11-18 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドおよび第ｘｉ因子ポリペプチドを含んでなる医薬組成物
US20040101546A1 (en) * 2002-11-26 2004-05-27 Gorman Anne Jessica Hemostatic wound dressing containing aldehyde-modified polysaccharide and hemostatic agents
JP2006515309A (ja) 2002-12-31 2006-05-25 マリン ポリマー テクノロジーズ，インコーポレーテッド 止血剤組成物およびその使用
GB0324044D0 (en) 2003-10-14 2003-11-19 Astrazeneca Ab Protein
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
RU2347574C2 (ru) 2004-05-27 2009-02-27 Эвиджен, Инк. Способы лечения коагулопатий с использованием сульфатированных полисахаридов
WO2006114105A2 (en) 2005-04-26 2006-11-02 Maxygen Holdings Ltd. Use of modified factor vii for treating bleeding
MX2008006313A (es) 2005-11-15 2008-11-06 Philadelphia Children Hospital Metodos y composiciones para modular la hemostasia.
CA2644926A1 (en) * 2006-03-06 2007-09-13 Humagene, Inc. A method for the preparation of recombinant human thrombin and fibrinogen
US20080014251A1 (en) 2006-07-14 2008-01-17 Advanced Vascular Dynamics Hemostatic compound and its use
US20090148502A1 (en) 2006-10-23 2009-06-11 Hemo Nanoscience, Llc Compositions and methods for treating lacerations, abrasions, avulsions, burns, ulcers, and cases of excessive bleeding
EP1935429A1 (en) 2006-12-22 2008-06-25 CSL Behring GmbH Synergistic therapeutic use of prothrombin complex concentrates with FVIII concentrates
CA2682405A1 (en) 2007-03-30 2008-10-09 Thrombodyne, Inc. Methods of making concentrated fibrinogen containing compositions and associated systems for preparing fibrin glue
BRPI0810172A2 (pt) 2007-04-13 2014-10-14 Catalyst Biosciences Inc Polipeptídeos de fator vii modificado e seus usos
US8852558B2 (en) 2008-03-11 2014-10-07 Materials Modification, Inc. In situ formation of an artificial blockage to control bleeding by polymer expansion with hydrogen peroxide and platinum catalyst
WO2010042741A1 (en) 2008-10-08 2010-04-15 Thrombodyne, Inc. Methods of making concentrated fibrinogen- and platelet containing compositions
PL2624859T3 (pl) 2010-10-06 2017-09-29 Medimmune Limited Czynnik ii samodzielnie lub w skojarzeniu z dalszymi czynnikami do leczenia zaburzeń hemostazy powiązanych z koagulopatią z rozcieńczenia

Also Published As

Publication number Publication date
US9433664B2 (en) 2016-09-06
HUE033204T2 (en) 2017-11-28
MX2013003715A (es) 2013-09-26
JP6000259B2 (ja) 2016-09-28
SG188639A1 (en) 2013-05-31
MX343784B (es) 2016-11-23
CN103221061A (zh) 2013-07-24
WO2012045569A1 (en) 2012-04-12
US20130280236A1 (en) 2013-10-24
RU2013120033A (ru) 2014-11-20
EP2624859A1 (en) 2013-08-14
DK2624859T3 (en) 2017-06-06
WO2012045569A9 (en) 2016-01-07
EP2624859B1 (en) 2017-03-01
SG10201508159SA (en) 2015-10-29
ES2625153T3 (es) 2017-07-18
RU2606155C2 (ru) 2017-01-10
PL2624859T3 (pl) 2017-09-29
AU2011313505A1 (en) 2013-04-11
CA2812888A1 (en) 2012-04-12
JP2013538863A (ja) 2013-10-17
KR20130136988A (ko) 2013-12-13
AU2011313505B2 (en) 2015-09-17

Similar Documents

Publication Publication Date Title
BR112013027119A2 (pt) novos conjugados ligante-droga (adcs) e uso dos mesmos
BR112014032699A2 (pt) métodos de tratamento de síndrome metabólica pediátrica
BR112014033102A2 (pt) produto para uso no tratamento profilático ou terapêutico de uma emoção negativa ou comportamento introvertido
BR112013008034A2 (pt) método para normalizar hemeostase comprometida
PL385586A1 (pl) Nowe analogi insuliny o przedłużonym działaniu
MX2013004699A (es) Combinaciones farmaceuticas para el tratamiento de trastornos metabolicos.
BR112013025047A2 (pt) composições nutricionais para aumentar os níveis de arginina e métodos para usar as mesmas
NZ630239A (en) Methods of treating melanoma
UY32497A (es) "2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso"
NZ602219A (en) Methods and compositions for treating degos’ disease
BR112015005940A2 (pt) processo para a preparação de nanopartículas terapêuticas
BRPI0901553A2 (pt) máscara facial
NZ598348A (en) Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels
CO6781465A2 (es) Composición farmacéutica, métodos de tratamiento y usos de la misma
BR112013020586A2 (pt) Uso de células derivadas de tecido do cordão umbilical
BR112012029975A2 (pt) peptídeo como medicamento, em particular para o tratamento do câncer.
DOP2006000057A (es) Composición farmaceútica para el tratamiento del cáncer
MX2019005300A (es) Polimeros enlazados al proton para administracion oral.
UY32237A (es) Compuestos de arilo con sustituyentes heterociclicos y su uso
BR112014003071A2 (pt) tratamento de doença vascular periférica com o uso de células derivadas do tecido do cordão umbilical
BR112013026976A2 (pt) alfa glucosidade ácida modificada com processamento acelerado
BR112018067906A2 (pt) métodos de tratamento de depressão usando antagonistas do receptor de orexina-2
BR112012013487A2 (pt) Composições de amantadina e métodos de uso
BR112013021661A2 (pt) objetivação de fator de coagulação a tlt-1 sobre plaquetas ativadas
EA201401231A1 (ru) Фармацевтические комбинации, предназначенные для лечения метаболических нарушений

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2532 DE 16-07-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.